MedPath

Electrical Resynchronization and Acute Hemodynamic Effects of Direct His Bundle Pacing Compared to Biventricular Pacing

Not Applicable
Completed
Conditions
Cardiac Resynchronization Therapy
Direct His Bundle Pacing
Cardiac Pacing, Artificial
Interventions
Device: Pacing
Registration Number
NCT03452462
Lead Sponsor
University Hospital, Geneva
Brief Summary

The aims are to compare Direct His Bundle Pacing (DHBP) with biventricular pacing (BiV) in terms of electrical resynchronization using electrocardiographic imaging (ECGI) and also in terms of acute hemodynamical effect using finger plethysmography and conduction velocimetry. The study will be a randomized crossover design with acute measurements.

Detailed Description

By recruiting native conducting tissue to relay electrical activation of the ventricles via the Purkinje fibre network, DHBP may potentially achieve greater electrical resynchronization and hemodynamic benefit compared to BiV where the electrical activation wavefronts propagate from two discrete pacing sites. Electrical synchrony achieved by these pacing modes have however never been compared. Furthermore, the acute hemodynamic effect of DHBP has been compared to BiV only in a small single study to date. The aims are to compare DHBP with BiV in terms of electrical resynchronization using electrocardiographic imaging (ECGI) and also in terms of acute hemodynamical effect using finger plethysmography and conduction velocimetry. The primary endpoint will be left ventricular activation time, with secondary endpoints including various electrical (right ventricular activation time, total ventricular activation time etc) and hemodynamic parameters (systolic pressure, cardiac output, cardiac contractility). It is expected that DHBP offers shorter left ventricular activation time (i.e. better synchrony) and hemodynamic benefit compared to BiV.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
19
Inclusion Criteria
  • Treatment of heart failure with a standard indication for CRT (NYHA III-IV, LVEF < 35% and QRS > 130ms; or LVEF< 40% and requirement for frequent ventricular pacing, irrespective of baseline QRS duration) and optimal medical treatment.

    • Permanent atrial fibrillation (allowing connection of the DHBP lead to the atrial port).
    • Patients implanted with 1) a CRT pacemaker or CRT defibrillator 2) a His lead with selective or non-selective DHBP, connected to the atrial port of the generator 3) a functional right ventricular lead and 4) a functional coronary sinus lead.
    • DHBP with selective or non-selective His capture
Exclusion Criteria
  • Age <18 years
  • Pregnancy
  • Inability to undergo CT or an MRI (e.g. due to severe claustrophobia)
  • Inability or refusal to sign the patient informed consent form.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Direct His Bundle PacingPacingPacing from the His bundle lead
Biventricular PacingPacingPacing from the right ventricular and coronary sinus leads
Primary Outcome Measures
NameTimeMethod
Left ventricular activation time5 minutes

Duration of left ventricular electrical activation

Secondary Outcome Measures
NameTimeMethod
Right ventricular activation time5 minutes

Duration of right ventricular electrical activation

Cardiac output5 minutes

Cardiac output measured by conductive velocimetry

Systolic pressure5 minutes

Systolic blood pressure measured by finger plethysmography

Total ventricular activation time5 minutes

Duration of total ventricular electrical activation

Cardiac contractility5 minutes

Cardiac contractilit measured by conductive velocimetry

Trial Locations

Locations (1)

University Hospital Geneva

🇨🇭

Geneva, GE, Switzerland

© Copyright 2025. All Rights Reserved by MedPath